ExploreWatchlistsPricing
  1. JP-listed companies
  2. Astellas Pharma Inc.
  3. Financials
  4. Total liabilities

Astellas Pharma Inc. (4503)

Market cap
¥4.63T
P/E ratio
18.3x
Astellas Pharma develops, manufactures, and sells pharmaceutical products globally through a network of 77 subsidiaries across the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal liabilities (Million JPY)YoY (%)
Mar 31, 20251,826,289-7.46%
Mar 31, 20241,973,615+108.06%
Mar 31, 2023948,564+8.77%
Mar 31, 2022872,087-1.74%
Mar 31, 2021887,513-13.75%
Mar 31, 20201,028,992+60.97%
Mar 31, 2019639,252+8.36%
Mar 31, 2018589,916-3.01%
Mar 31, 2017608,221+10.30%
Mar 31, 2016551,432+77.12%
Mar 31, 2015311,340

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat